Get the Stockscreener App
1.56
7.93%
0.11
Ocugen Inc stock is traded at $1.56, with a volume of 5.46M.
It is up +7.93% in the last 24 hours and up +28.28% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.45
Open:
$1.46
24h Volume:
5.46M
Relative Volume:
1.31
Market Cap:
$488.78M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-5.7778
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
+14.23%
1M Performance:
+28.28%
6M Performance:
+63.53%
1Y Performance:
+73.97%
1-Day Range:
$1.45
$1.58
1-Week Range:
$1.32
$1.58
52-Week Range:
$0.515
$1.90
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.565 | 452.86M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.21 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.83 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.25 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.32 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.76 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments - Seeking Alpha
Could Ocugen Offer A Vision Of Growth With 2026 Catalysts Approaching? - RTTNews
Ocugen Shares Face Pressure Following Strong Advance - AD HOC NEWS
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment - MSN
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Market Outlook: Can Pharmaron Beijing Co Ltd 17Q1 stock expand revenue streamsQuarterly Investment Review & Expert Approved Momentum Trade Ideas - moha.gov.vn
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen’s Pivotal Year: Clinical Data and Financial Runway in Focus - AD HOC NEWS
Ocugen stock surges 75% year to date: What's in store for 2026? - MSN
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen’s Gene Therapy Pipeline Drives Investor Optimism - AD HOC NEWS
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? - The Globe and Mail
Ocugen Shares Test Critical Technical Floor - AD HOC NEWS
Ocugen Sees Unusually High Options Volume (NASDAQ:OCGN) - MarketBeat
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Shares Navigate Year-End Consolidation Phase - AD HOC NEWS
Ocugen Inc. Stock Falls Tuesday, Underperforms Market - 富途牛牛
Ocugen’s Pipeline Progress: Targeting Unmet Needs in Rare Eye Diseases - AD HOC NEWS
Is Ocugen’s (OCGN) Rare Disease Summit Spotlight Reframing Its Gene Therapy Investment Narrative? - Yahoo Finance
Is Ocugen (OCGN) Quietly Reframing Its Risk Profile Around Rare Disease Gene Therapies? - simplywall.st
Why Ocugen Inc. stock is a must watch in 2025Energy Sector Updates & Achieve Triple Digit Returns - bollywoodhelpline.com
Why Ocugen Inc. (2H51) stock stays on top picksOptions Play & Community Verified Trade Signals - Улправда
Can Ocugen Inc. stock weather global recession2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Bear Alert: Can Ocugen Inc. stock weather global recessionJuly 2025 Weekly Recap & Risk Managed Investment Strategies - Улправда
Will Ocugen Inc. stock deliver strong dividend growth2025 Macro Impact & Verified Trade Idea Suggestions - Улправда
Ocugen Ties CEO Compensation to Regulatory and Stock Performance - AD HOC NEWS
Is Ocugen Inc. (2H51) stock dividend growth reliable2025 Trading Volume Trends & Technical Entry and Exit Tips - DonanımHaber
Why Ocugen Inc. (2H51) stock is listed among top recommendationsMarket Performance Summary & Weekly Consistent Profit Watchlists - DonanımHaber
Will Ocugen Inc. stock maintain growth story2025 Risk Factors & Low Drawdown Trading Strategies - DonanımHaber
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Grants CEO New Performance-Based Equity Award - TipRanks
Pharma News: Why Ocugen Inc. stock is a must watch in 2025July 2025 Summary & Risk Adjusted Buy and Sell Alerts - Улправда
Why pension funds invest in Ocugen Inc. (2H51) stockAnalyst Upgrade & Safe Entry Trade Reports - Улправда
Ocugen Shares Face Mounting Pressure Amid Financial Concerns - AD HOC NEWS
Ocugen Inc. Stock Rises Tuesday, Outperforms Market - 富途牛牛
Ocugen Inc. Stock Rises Monday, Outperforms Market - 富途牛牛
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 - Nasdaq
Ocugen (NASDAQ:OCGN) Shares Up 1.5%What's Next? - MarketBeat
How The Latest Analyst Shifts Are Reshaping Ocugen’s Story and Valuation - Yahoo Finance
Ocugen Inc Stock Analysis and ForecastSector Rotation Strategies & Free Rapid Growing Investment Returns - earlytimes.in
Growth Recap: Is Ocugen Inc stock supported by strong cash flowsJuly 2025 Review & Stepwise Trade Execution Plans - moha.gov.vn
Institutional Giant Janus Henderson Makes Major Bet on Ocugen - AD HOC NEWS
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Ocugen I - GuruFocus
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen CEO’s Keynote Address Meets Heightened Market Skepticism - Ad-hoc-news.de
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen
Ocugen, Inc. Chairman and CEO Dr. Shankar Musunuri to Present at Oppenheimer Movers in Rare Disease Summit - Quiver Quantitative
Major Fund Manager Acquires Significant Stake in Ocugen Amid Share Price Weakness - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen Inc. Stock Falls Friday, Underperforms Market - 富途牛牛
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):